Difference between revisions of "Editing test page 2"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 1: Line 1:
 +
'''Use of this site is subject to you reading and agreeing with the terms set forth in the [[HemOnc.org_-_A_Hematology_Oncology_Wiki:General_disclaimer|disclaimer]]. If this is your first time visiting, we suggest you read the [[tutorial]].'''
  
 +
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are [[How_to_contribute|invited to contribute to the site]].
  
−
{|style="width: 100%; border-left:solid 20px #dc143c;border-right:solid 20px #dc143c;border-top:solid 20px #dc143c;border-bottom:solid 20px #dc143c;" align="center"  
+
{| class="wikitable" style="text-align:center; width:50%;"
−
|
+
!colspan="2" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Section editor'''
−
<span style="font-family:Arial; font-size:200%">&nbsp;Hello!<br>
+
|-
−
&nbsp;We're happy that you've chosen to use HemOnc.org, and hope that you will return often. From now until January 31, we are conducting a survey to learn more about our users and how we can make the site better and more useful.<br>
+
|style="background-color:#F0F0F0"|[[File:nkv.jpg|thumb|upright=0.3|center]]
−
&nbsp;Please help us by filling it out!<br>
+
|<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>Chicago, IL</big>
−
&nbsp;'''Link:''' http://j.mp/2BlBaoQ
+
|-
−
</span>
 
 
|}
 
|}
 +
 +
<big>Note: the page has adjuvant and perioperative regimens specific to colon cancer as well as systemic regimens for the more general category of colorectal cancer. Please see the [[Rectal_cancer|'''rectal cancer page''']] for regimens specific to rectal cancer.</big>
 +
{| class="wikitable" style="float:right; margin-right: 5px;"
 +
|-
 +
|<div style="background-color: #66FF66; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} regimens on this page</b></font></div>
 +
<div style="background-color: #66CCFF; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} variants on this page</b></font></div>
 +
|}
 +
{{TOC limit|limit=3}}
 +
 +
=Guidelines=
 +
==[http://www.esmo.org/ ESMO]==
 +
*[http://annonc.oxfordjournals.org/content/24/suppl_6/vi64.full.pdf+html Early Colon Cancer: ESMO Clinical Practice Guidelines] [https://www.ncbi.nlm.nih.gov/pubmed/24078664 PubMed]
 +
*[http://annonc.oxfordjournals.org/content/27/8/1386.full.pdf+html ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.] [https://www.ncbi.nlm.nih.gov/pubmed/27380959 PubMed]
 +
*[http://annonc.oxfordjournals.org/content/24/suppl_6/vi73.full.pdf+html Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines.] [https://www.ncbi.nlm.nih.gov/pubmed/23813931 PubMed]
 +
 +
==[https://www.nccn.org/ NCCN]==
 +
*[https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf NCCN Guidelines - Colon Cancer]
 +
 +
=Adjuvant therapy=
 +
==Capecitabine monotherapy {{#subobject:7b50df|Regimen=1}}==
 +
{| class="wikitable" style="float:right; margin-left: 5px;"
 +
|-
 +
|[[#top|back to top]]
 +
|}
 +
===Regimen {{#subobject:ed4e3f|Variant=1}}===
 +
{| class="wikitable" style="width: 100%; text-align:center;"
 +
!Study
 +
![[Levels_of_Evidence#Evidence|Evidence]]
 +
!Comparator
 +
![[Levels_of_Evidence#Efficacy|Efficacy]]
 +
|-
 +
|[http://www.nejm.org/doi/full/10.1056/NEJMoa043116 Twelves et al. 2005]
 +
|style="background-color:#1a9851"|Phase III
 +
|[[#Fluorouracil_.26_Folinic_acid|5-FU & Leucovorin]]
 +
|style="background-color:#eeee01"|Non-inferior DFS
 +
|-
 +
|[http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30172-3/fulltext Kerr et al. 2016 (QUASAR 2)]
 +
|style="background-color:#1a9851"|Phase III
 +
|Capecitabine & Bevacizumab
 +
|style="background-color:#ffffbf"|Seems not superior
 +
|-
 +
|}
 +
====Chemotherapy====
 +
*[[Capecitabine (Xeloda)]] 1250 mg/m<sup>2</sup> PO BID on days 1 to 14
 +
 +
'''21-day cycle for 8 cycles'''
 +
 +
===References===
 +
# Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. [http://www.nejm.org/doi/full/10.1056/NEJMoa043116 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15987918 PubMed]
 +
# Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016 Nov;17(11):1543-1557. [http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(16)30172-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27660192 PubMed]

Revision as of 19:42, 10 January 2018

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Section editor
Nkv.jpg
Neeta K. Venepalli, MD, MBA
Chicago, IL

Note: the page has adjuvant and perioperative regimens specific to colon cancer as well as systemic regimens for the more general category of colorectal cancer. Please see the rectal cancer page for regimens specific to rectal cancer.

1 regimens on this page
1 variants on this page


Guidelines

ESMO

NCCN

Adjuvant therapy

Capecitabine monotherapy

back to top

Regimen

Study Evidence Comparator Efficacy
Twelves et al. 2005 Phase III 5-FU & Leucovorin Non-inferior DFS
Kerr et al. 2016 (QUASAR 2) Phase III Capecitabine & Bevacizumab Seems not superior

Chemotherapy

21-day cycle for 8 cycles

References

  1. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005 Jun 30;352(26):2696-704. link to original article contains verified protocol PubMed
  2. Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol. 2016 Nov;17(11):1543-1557. link to original article contains protocol PubMed
Retrieved from "https://hemonc.org/w/index.php?title=Editing_test_page_2&oldid=22288"